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Abstract 
Background: 
The twentieth century saw changes which transformed unregulated and 
unethical research in ways which could only be welcomed. The burden of 
paperwork, however, risked the near universal buy-in to ethical governance 
being seen as an obstacle rather than a facilitator.  
Objective  
We sought to record and understand delays, variations in practice, and time 
costs in relation to research governance approval of a low-risk study during a 
time of organisational change. 
Design: Review of recruitment notes.  
Setting: Research and Development (R&D) departments UK National Health 
Service hospital trusts.  
Main outcome measures: Number of contacts required to achieve an interview 
with NHS employee(s)  
Results  
The ratio of contacts to interviews was 16.5:1. Although we did not formally cost 
the time taken to (under) achieve our sample, we estimate that it doubled the 
time we had budgeted for this relatively small low-risk project. Once we reached 
a contact in an R&D department, colleagues were risk averse, but helpful in 
trying to make this study work, in some cases, suggesting workarounds. 
Conclusions Our difficulties in securing relevant permissions for interviews 
suggest that a report contributing to the literature on checks and balances in 
good research governance during a time of organisational change, and possible 
mitigation is worth undertaking .The ‘bureaucracy busting’ measures in Best 
Research for Best Health remain a work in progress. Drawing on notions of trust 
and proportionality, we suggest that, for low risk studies, the costs to 
researchers, to R&D colleagues and to R&D funders could be reduced without 
increasing risks to participants. A postscript to our conclusion comes from the 
Health Research Authority, who currently have a major programme of change 
designed to enable the kinds of change which both protects participants and 
enables research. 
 
Background 
 
Much of the discussion about the burden of paperwork in ethical approval of 
research studies has been around the need to balance timely research and 
encouragement of innovation with the need to protect participants and prevent 
research fraud. The worst outcome of attempts at improving governance, as one 
of us has pointed out in a different context, is that research becomes more 
difficult to undertake.1 In a climate of austerity combined with rising research 
costs, it also becomes more expensive. There are, of course, wider implications of 
the growth of bureaucracies, limits to trust and professionalism, and the costs to 
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academics, clinicians, research participants, some of which were set out in a 
recent evaluation2 of the delays and variations in practice attributable to 
research governance approval of clinical trials in the United Kingdom. The 
authors concluded that: The UK research governance system incurs unacceptably 
long and costly delays…’ suggesting that urgent reform, including uniform 
implementation of the ‘bureaucracy busting’ measures in Best Research for Best 
Health, were needed.3  
 
Our study 
 
A decade on from Best Research for Best Health, and following further reports on 
increasing efficiency and reducing bureaucracy in research governnance,4 5 6 we 
carried out a low-risk, non-clinical study of paediatric policies in the public 
domain. The aim of the study was to understand the ways in which particular 
guidelines operated and were interpreted on the ground.  This was a two stage 
study: the first comprised documentary review (which did not require formal 
ethical review); the second, interviews with NHS staff who wrote the policies, 
implemented them on the front line as clinicians or administrators and/or had 
responsibility for strategic implementation of the policies. We gained ethical 
approval for the project from UCL Ethics Committee, who permitted us to seek 
verbal consent only in approaching interviewees. We were, in addition, required 
to secure two other forms of approval, one relating to data 
protection/information governance, and the other from Great Ormond Street 
Hospital for Children/UCL Institute of Child Health/ (GOSH/ICH) R&D office. The 
latter required us to secure permission from leads in R&D offices of each Trust 
before we approached prospective interviewees. 
 
 
Having searched for guidelines on the topic of interest in the public domain in all 
English trusts, we identified 24 guidelines that met our inclusion criteria. We 
downloaded and described the contents of these, and then set about trying to 
contact potential interviewees.  
 
We contacted the relevant trust R&D offices by email using contact names on the 
R&D forum (http://www.rdforum.nhs.uk). In all, 47 organisations were 
contacted over a three month period and experienced significant recruitment 
problems at the commencement of this stage. The current report, in which we 
describe the delays, variations in practice, and time costs we experienced, is a 
by-product of the original study (UCL Ethics Committee agreed that we did not 
need to seek additional ethics permission to report on our difficulties).  
 
Method: Review of recruitment notes collected during the second stage of our 
study. This involved a review of both electronic and paper-based records.  
 
Results 
 
We encountered significant problems with recruitment at the interview stage. To 
interview eight respondents, we initiated 131 contacts, giving a ratio of contacts 
to interviews of 16.5:1.  
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Our difficulties were undoubtedly exacerbated by the re-organisation brought 
about by the Health and Social Care Act (2012), within the NHS, but many of our 
difficulties replicated those encountered by previous researchers. Difficulties in 
making the initial contact were experienced at both the R&D approval stage, and 
in relation to approaching prospective interviewees.  
 
In respect of the first, a common problem we experienced was email messages 
returned as ‘unknown addressee’. Table 1 shows the full range of responses. 
Briefly, these included: 
 
 Multiple first R&D contacts forwarding our message to colleagues, 
and suggestions of who else might be approached; 
 Requests for Integrated Research Approval System (IRAS) or other 
written information;  
 In principle approval, so long as we only conducted a telephone 
interview; 
 Only one R&D office declined our approach to interview staff on 
the basis of volume of studies they needed to consider. They too 
made helpful suggestions; 
 One query about whether the study was part of NIHR portfolio; 
 A query about whether the study  needed to come to R&D for 
approval (and, in some cases, a suggestion that that the study 
might be re-defined as ‘not research’ to facilitate faster progress; 
 Although only one R&D department declined, others simply ran 
into the sands as our attempts to contact R&D departments by 
telephone and email – and the contacts we were then passed onto, 
became increasingly unproductive. 
 
Once an R&D department had agreed to let us go ahead (sometimes providing us 
with contacts in addition to, or instead of, those named in the guidelines), the 
remaining delays related in the main to the workloads of those we were 
interviewing, although all respondents were generous with their time. Our poor 
ability to recruit resulted in our extending our search through snowballing in the 
trust with which one of us (HR) holds an honorary contract. This was an 
approach for which had ethical approval but one which we had hoped to avoid 
on the grounds of potential bias This method was rapidly productive of 3 
illuminating interviews.  
 
Table 1 describes our contacts with R&D departments. 
 
Discussion 
 
The history of the formal ethical oversight of research both within and outside 
the clinic is relatively recent in terms of its formal structures. Previous reports 7 8 
9 10 have described what can be a heavy burden of requirements, and our data on 
the difficulties of tracking down the right people (and variations in what R&D 
departments consider to be the ‘right’ answer) suggest that bureaucracy-busting 
has some way to go. As Macdonach et al 7 point out, over-regulation may result in 
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undesirable side effects – including the temptation by researchers or R&D 
colleagues to re-nominate work as ‘not research’ as a 'workaround' measure. 
 
All approaches to R&D were made by the investigators themselves rather than 
delegated to colleagues who were newer to the field. We were experienced 
researchers doing a low-risk study. Those we were interviewing are busy people, 
and it is right that they should have the right to turn down participation, but 
what we were requesting from R&D departments was not permission to 
interview their staff, but permission to approach staff to request an interview. 
This is itself raises ethical issues about the appropriate level for decision-making 
in organisations and the nature of trust. 
 
At a meeting to celebrate 50 years of the National Children’s Bureau,11 a young 
person was reported as having said “If you stopped doing stupid stuff or doing 
stuff in a stupid way, you would have time for the important stuff.’ Ethics and 
good governance, is not, of course ‘stupid stuff,’ But an increasing distance 
between the core business of academic, NHS and other public sector 
organisations and their governance carries risks. This is a relatively minor 
example, but a costly one.   
 
Conclusions 
 
Our experience suggests the following, most of which in one form or another, 
have also been raised by other researchers over the last couple of decades. 
However, despite the need for originality, repeated messages (as Coca Cola and 
the tobacco and alcohol industries have found) may be helpful in implanting an 
idea. 
 
 The need for continuous dialogue with both researchers and researched 
on fine-tuning systems in the light of the everyday research practice.  
 Whilst the requirement for R&D departments to be involved in addition to 
ethical approval may make the governance trail for research which hits 
the headlines clearer, judgement is needed on proportionality. 
 Cost consequences studies of the very substantial time invested in 
reseach governance in low or no risk studies needs to be assessed. 
 Ethics reviews for low-risk, non-clinical studies are now streamlined. 
(Ours was granted chair’s approval).  
 
The time taken in tracing and following up R&D contacts during a period of 
considerable churn in the NHS was substantial for both researchers and R&D 
colleagues. This is not a new problem, and one can acknowledge the reasons for 
risk aversion whilst deploring some of its consequences.  
 
In her 2002 Reith lectures12, Onora O’Neill pointed out that every day we read of 
untrustworthy action by politicians and officials, by hospitals and exam boards, 
by companies and schools. … Everyday we also read of aspirations and attempts 
to make business and professionals, public servants and politicians more 
accountable in more ways to more stakeholders. Her conclusion is that we need 
to think less about accountability through micro-management and central 
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control, and more about good governance. If we are to restore trust we shall 
have to start communicating in ways that are open to assessment.  
 
In thinking about these problems, HR and TS made contact with the Health 
Research Authority (HRA). As a result of our discussion, we add a cautiously 
optimistic response and illustrative case study from JW. 
 
The HRA was established in December 2011 to promote and protect the interests of 
patients and the public in health research and to streamline the regulation and 
governance of research. Its establishment was part of a response to the Academy of 
Medical Sciences review of the regulation and governance of health research, 
which called for the removal of barriers to research where researchers had to 
navigate complexities to get permission to conduct research in the NHS.  
 
HRA Approval is a new operational service which will streamline the process 
through which permission is achieved from the NHS in England. HRA Approval 
brings together the assessment of governance and legal compliance, with the 
independent REC opinion. 
 
Value can be demonstrated by learning from case studies. The HRA in the course of 
exploring how systems might be improved, found examples where inefficiencies 
resulted in inexcusable and unjustifiable delays and burdens for researchers 
seeking to deliver studies without clinical interventions, and where these studies 
provide insights into the change of approach and culture required.  
 
The study described above will be a familiar story to readers, but how would we 
expect it to have fared as an HRA Approval study?  I respond with reference to a 
study that went through HRA Approval in the first cohort of a move to streamline 
systems. 
 
The study: A short online survey sent to the Senior Nurse, Chief Nurse or Director of 
Nursing 
Target: All secondary care Trusts in England 
 
There was no requirement for a principal investigator or local collaborator and no 
support was required locally  
 
HRA Approval was issued 15 days after submission and the HRA determined that 
participating NHS organisations in England did not need to confirm capacity and 
capability to host the research. It was expected that each NHS Trust would become 
a participating NHS organisation 35 days after submission by the sponsor to the 
HRA, unless justification could be provided to the sponsor and the HRA as to why 
the organisation could not participate. All NHS Trusts in England automatically 
became sites unless they opted out with clear justification.  
 
NHS Trusts were sent the HRA Approval letter and Statement of Activities via 
contact details on the R&D forum website. In addition, as a study coming through 
very early in the roll out process the HRA provided change leads notified their local 
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change contacts in advance (this is additional support to facilitate change to the 
new processes). 
 
The HRA received a number of requests for further information and for copies of 
the study documentation. Requests for the study documentation were refused in all 
cases, gently with explanation as to why they were not required locally. There were 
a number of requests for clarification and assurance e.g. confirming the staff 
involved and the HRA agreed to provide the IRAS form so that locally there could be 
confidence in our assurance. Some wanted these details so they could fulfil roles to 
support the study and encourage participation. 
 
From all secondary care Trusts sent the information only 5 declined to participate. 
Accepting that this was local facilitation by the change leads it is nevertheless a 
very encouraging result which shows great promise for a radically simplified 
approach of genuine and considerable benefit for researchers conducting these 
non-clinical studies.  
 
So, what of the 5 that declined? The duties in the Care Act that established the HRA 
as a Non –Departmental Public Body provide a platform through which others 
have duty to regard our guidance. In due course we may look to rely on these duties 
more directly. For now we seek to work with colleagues to understand and learn, to 
build on relationships and expertise to change culture and ensure that we build a 
platform for the new approach that has a shared understanding and support. 
Interestingly, the 5 that declined were largely based on policies that did not 
empower a sensible interpretation. We know it is early days but the signs are good 
and we welcome feedback from all that are working through the new processes. 
Early feedback is essential whilst we have the additional programme resources in 
place to address the issues we fully expect to be raised for and that we will need to 
resolve. 
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Table 1: Contacts to harvested interview 
 
Organisations  Number 
of  
contacts 
IRAS or other 
info required  
  
Interview 
yield 
Acute Trust1  4  IRAS + additional 
Information 
N 
Acute Trust2 4 IRAS + additional 
Information 
N 
Acute Trust4 7 Additional information N 
Acute Trust5 3 Asked for original information to be 
re-sent 
N 
Acute Trust9 6 IRAS N 
Acute Trust10 3 No – passed on to R&D manager N 
Acute Trust12  10 Passed to additional colleagues 
including information governance 
manager  
Y 
Acute Trust13 6 Very interested and passed onto 3 
colleagues 
N 
Acute Trust14 5 Declined on grounds that 
organisation receives too many 
requests 
N 
Acute Trust15 5 Requested further documents N 
Acute Trust16 8 Department short staffed and our 
contact away 
N 
CCG2 10 Passed through several contacts and 
phone numbers 
Y 
CCG3 1 Unproductive contact N 
CCG4 2 Unproductive contacts N 
CCG5 4 Unproductive multiple contacts N 
CCG6 3 Suggestion to contact provider 
services 
N 
MHT1 9 Multiple follow ups N 
MHT2  1 IRAS required N 
MHT3 4 3 interviewees (one paired) Yx3 
MHT5 5 Multiple contacts N 
MHT7 7 Multiple contacts; IRAS required N 
MHT8 6 Multiple contacts N 
MHT9 6 Asked if project will become part of 
NIHR portfolio given DH funding 
N 
HCT1 7 Multiple contacts N 
Other trust 5 Snowballing contacts Y x3 
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